TransUnion Q4 Earnings Up; Guides Q1 FY26

TransUnion reported a stronger fourth quarter with net income attributable to the company rising to $101.2M ($0.52/share) from $66.2M ($0.34) a year earlier, revenue up to $1.17B, adjusted net income of $208.4M and adjusted EBITDA of $416.7M. The company declared a $0.125 quarterly cash dividend (payable Mar 13, record Feb 26) and issued constructive guidance: Q1 2026 revenue of $1.195–1.205B (9–10% growth) with adjusted EPS $1.08–1.10, and full-year 2026 revenue of $4.946–4.981B (+8–9%) with adjusted EPS $4.63–4.71 (+8–10%) and net income $538–553M (+18–21%). Despite the upbeat results and solid full-year outlook, management flagged Q1 GAAP net income to decline year‑over‑year, and shares were modestly weaker in pre-market trading.

Analysis

Market structure: TransUnion (TRU) is a direct beneficiary of secular demand for granular consumer and commercial data — lenders, fintechs, fraud vendors and analytics platforms gain. Competitors (EFX, EXPGY) face intensified pricing competition where switching costs favor firms with broader product suites; constrained supply of quality, privacy-compliant data could raise pricing power 3-7% over 12–24 months.

Risk assessment: Key tail risks are regulatory enforcement (CFPB/EU privacy fines >$500M) and a material data breach (> $1B, multi-quarter customer churn). Immediate horizon (days) will show sentiment volatility after the Q1 GAAP dip; over 3–12 months macro-driven credit stress could compress revenues, while FY2026 guidance implies durable margin expansion if lending volumes hold.

Trade implications: Constructive on TRU at ~70.75 given FY26 adjusted EPS guidance (~$4.63–4.71 → ~15x P/E). Tactical portfolio: establish 2–3% long TRU (6–12 month target +25–35%), hedge with 9–12 month 60 puts if downside >20% feared. Consider a cost-limited bullish call spread (buy Jul-2026 70 call, sell Jul-2026 90 call) sized to 1% NAV and a pair trade — long TRU / short EFX (0.6x) to capture relative execution.

Contrarian angles: Market may over-penalize the Q1 GAAP net income decline — consensus is underweight recurring adjusted EBITDA growth (guidance +8–10%). Conversely, the market likely underestimates regulatory tail risk; if FCF conversion falls below 50% of EBITDA over next four quarters, downgrade to neutral and reduce exposure by 50%. Historical parallel: Equifax post-breach recovery shows long-term resilience but long drawdowns possible.

Key Decisions for Investors

• Establish a 2–3% long position in TRU (buy at market ~70.75) targeting 25–35% upside over 6–12 months; set a hard stop-loss at 12% below entry (~62) and take profits incrementally at +20% and +30%.
• Implement a bullish, limited-risk options trade: buy Jul-2026 TRU 70 calls and sell Jul-2026 90 calls (call spread) sized to equal 1% of NAV to capture upside while capping cost; close if spread reaches 70% of max value or at 12 months.
• Execute a pair trade: long TRU vs short EFX (Equifax) sized 1:0.6 to neutralize beta — maintain for 3–9 months to exploit TRU's stronger guidance; rebalance if relative performance exceeds ±15%.
• Sell a cash-secured Nov-2026 TRU 65 put (or equivalent) to collect premium and potentially acquire shares at ~8% discount; abort if regulatory news implies potential fines >$500M or if FCF/EBITDA ratio drops below 50% over two consecutive quarters.
• Buy protective 9–12 month TRU puts struck at 60 (size 0.5–1% NAV) as insurance against a regulatory/breach scenario that could exceed 20–30% downside; reduce or remove hedge if no adverse regulatory actions materialize in 60 days.